Mutant prevention concentration: Comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 3, 2004, Pages 441-444

  Rodriguez J C ^a   Cebrian L ^a   Lopez M ^a   Ruiz, M ^a   Jimenez I ^a   Royo, G ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Drug activity; Fluoroquinolones; Oxazolidinones; Tuberculosis

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BACTERIUM MUTANT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DILUTION; INOCULATION; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

ACETAMIDES; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; TUBERCULOSIS;

EID: 1642351934     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh119     Document Type: Article

References (33)

1. Pablos Mendez, A., Raviglione, M. C., Laszlo, A. et al. (1998). Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization - International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. New England Journal of Medicine 338, 1641-9.
2. Dong, Y., Zhao, X., Domalaga, J. et al. (1999). Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 43, 1756-8.
3. Rodríguez, J. C., Ruiz, M., Climent, A. et al. (2001). In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. International Journal of Antimicrobial Agents 17, 229-31.
4. Rodríguez, J. C., Ruiz, M., López, M. et al. (2002). In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. International Journal of Antimicrobial Agents 20, 464-7.
5. Sindelar, G., Zhao, X., Liew, A. et al. (2000). Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Journal of Clinical Microbiology 44, 3337-43.
6. Sullivan, E. A., Kreiswirth, B. N., Palumbo, L. et al. (1995). Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 345, 1148-50.
7. Vernon, A., Burman, W., Benator, D. et al. (1999). Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 353, 1843-7.
8. La Creta, F. P., Kollia, G. D., Duncan, G. et al. (2000). Age and gender effects on the pharmacokinetics of gatifloxacin. Pharmacotherapy 20, 67-75.
9. Kennedy, N., Berger, L., Curram, J. et al. (1996). Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clinical Infectious Diseases 22, 827-33.
10. Bergstermann, H. & Ruchardt, A. (1997). Ciprofloxacin once daily versus twice daily for the treatment of pulmonary tuberculosis. Infection 25, 227-32.
11. Sirgel, F. A., Botha, F. J., Parkin, D. P. et al. (1997). The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 156, 901-5.
12. Israel, D., Gillum, G., Turik, M. et al. (1993). Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrobial Agents and Chemotherapy 37, 2193-9.
13. Birmingham, M. C., Guarino, R., Heller, A. et al. (1999). Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose. Journal of Antimicrobial Chemotherapy 43, 43-8.
14. Hansen, G. T., Metzler, K., Drlica, K. et al. (2003). Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 47, 440-1.
15. Gotfried, M. H., Danziger, L. H. & Rodvold, K. A. (2001). Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 119, 1114-22.
16. Firsov, A. A., Vostrov, S. N., Lubenko, I. Y. et al. (2003). In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 47, 1604-13.
17. Wise, R. (2003). Maximizing efficacy and reducing the emergence of resistance. Journal of Antimicrobial Chemotherapy 51, Suppl. S1, 37-42.
18. Hu, Y., Coates, A. R. & Mitchison, D. A. (2003). Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 47, 653-7.
19. Ballesta, S., Pascual, A., Garcia, I. et al. (1996). Penetracion de cinco fluoroquinolonas en polimorfonucleares humanos. Enfermedades Infecciosas y Microbiología Clínica 14, 470-3.
20. Lober, S., Ziege, S., Rau, M. et al. (1999). Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrobial Agents and Chemotherapy 43, 1067-71.
21. Soman, A., Honeybourne, D., Andrews, J. et al. (1999). Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. Journal of Antimicrobial Chemotherapy 44, 835-8.
22. Lutsar, I., Friedland, I. R., Wubbel, L. et al. (1998). Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrobial Agents and Chemotherapy 42, 2650-5.
23. Scotton, P. G., Pea, F., Giobbia, M. et al. (2001). Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis. Clinical Infectious Diseases 33, 109-11.
24. Cottagnoud, P., Gerber, C. M., Acosta, F. et al. (2000). Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model. Journal of Antimicrobial Chemotherapy 46, 981-5.
25. Lovering, A. M., Zhang, J., Bannister, G. C. et al. (2002). Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. Journal of Antimicrobial Chemotherapy 50, 73-7.
26. Yoshimatsu, T., Nuermberger, E., Tyagi, S. et al. (2002). Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrobial Agents and Chemotherapy 46, 1875-9.
27. Alvirez Freites, E. J., Carter, J. L. & Cynamon, M. H. (2002). In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 46, 1022-5.
28. Gee, T., Ellis, R., Marshall, G. et al. (2001). Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrobial Agents and Chemotherapy 45, 1843-6.
29. Honeybourne, D., Tobin, C., Jevons, G. et al. (2003). Intrapulmonary penetration of linezolid. Journal of Antimicrobial Chemotherapy 51, 1431-4.
30. Cynamon, M. H., Klemens, S. P., Sharpe, C. A. et al. (1999). Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrobial Agents and Chemotherapy 43, 1189-91.
31. Mitchison, D. A. (1998). How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. International Journal of Tuberculosis and Lung Disease 2, 10-5.
32. Zhao, X. & Drlica, K. (2001). Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies. Clinical Infectious Diseases 33, Suppl. 3, S147-56.
33. Ginsburg, A. S., Grosset, J. H. & Bishai, W. R. (2003). Fluoroquinolones, tuberculosis, and resistance. Lancet Infectious Diseases 3, 432-42.